EUVIMEDSkopri EUVIMED
MetaanalyseSystematische Übersicht

Paclitaxel‐Coated Balloon for the Management of In‐Stent Coronary Restenosis: An Updated Meta‐Analysis and Trial Sequential Analysis

Vinícius M R Oliveira, Arthur Marot Paiva, Pedro Lucas Alves Alencar, Izadora Caiado Oliveira, João Victor Alves Alencar, Felipe Schmaltz Zalaf, Ricardo Figueiredo Paro Piai, André Maroccolo de Sousa, Humberto Graner Moreira iD

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.31388 ↗

At a glance

Metaanalyse in Catheterization and Cardiovascular Interventions, 2025. Written by Vinícius M R Oliveira and 8 co-authors. Institution: Department of Medicine, Federal University of Goiás, Goiânia, Brazil. Major MEDLINE topics: Paclitaxel, Cardiovascular Agents, Coronary Restenosis, Coated Materials, Biocompatible. Cited 1 times so far (Crossref); 36 references. Funded by: The authors received no specific funding for this work..

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Drug‐coated balloons present a potentially advantageous therapeutic approach for managing coronary in‐stent restenosis (ISR). However, the comparative benefits of paclitaxel‐coated balloons (PCBs) over uncoated balloons (UCBs) remain unclear.

Aims

We conducted a systematic review and meta‐analysis to evaluate and compare the clinical outcomes of patients treated with PCBs and UCBs.

Methods

We systematically searched PubMed, Embase, and Cochrane for studies comparing PCBs and UCBs in managing coronary ISR. We used a random‐effects model to pool risk ratios (RRs) and their 95% confidence intervals (CIs). Statistical analyses were conducted using Review Manager 5.4.1. Heterogeneity was assessed using I 2 statistics. Quality and risk of bias were evaluated using the Cochrane Collaboration's tool.

Results

We included seven randomized controlled trials with 1349 patients, of whom 840 underwent percutaneous coronary intervention with PCB. In our pooled analysis, patients treated with PCB had lower risks of target lesion revascularization (RR 0.31, 95% CI 0.18–0.52; p < 0.01), target vessel revascularization (0.53, 0.42–0.67; p < 0.01), major adverse cardiac events (MACEs) (0.25, 0.16–0.38; p < 0.01), and myocardial infarction (MI) (0.59, 0.37–0.95; p = 0.03). However, there were no significant differences in all‐cause mortality (0.79, 0.37–1.70; p = 0.54), cardiac death (0.46, 0.03–8.12; p = 0.60), while tendencies for a significant difference were found for target lesion failure (0.39, 0.13–1.11; p = 0.08), or stent thrombosis (0.21, 0.03–1.35 p = 0.10).

Conclusion

These findings suggest that PCBs are superior to UCBs regarding the occurrence of target lesion revascularization, target vessel revascularization, MACEs, and MI, but they do not differ in all‐cause mortality, and cardiac death, while trends to significant differences favoring PCB were found to stent thrombosis and target lesion failure.

Subjects

MeSH terms (MEDLINE)

PaclitaxelCardiovascular AgentsCoronary RestenosisCoated Materials, BiocompatibleCardiac CathetersAngioplasty, Balloon, CoronaryPercutaneous Coronary InterventionCoronary Artery DiseaseStentsHumansRandomized Controlled Trials as TopicTreatment OutcomeRisk FactorsTime FactorsMaleMiddle AgedRisk AssessmentFemaleAged

Author keywords

balloonin‐stent coronary restenosismeta‐analysispaclitaxelpercutaneous coronary interventiontrial sequential analysis

Substances

PaclitaxelCardiovascular AgentsCoated Materials, Biocompatible

Authors and institutions

  • Department of Medicine, Federal University of Goiás, Goiânia, Brazil.
  • Department of Medicine, State University of Campinas, Campinas, Brazil.
  • Hospital Israelita Albert Einstein, São Paulo, Brazil.

ORCID profiles: Humberto Graner Moreira

Funding

  • The authors received no specific funding for this work.

Cite

APA

Oliveira, V. M. R., Paiva, A. M., Alencar, P. L. A., Oliveira, I. C., Alencar, J. V. A., Zalaf, F. S., Piai, R. F. P., de Sousa, A. M., & Moreira, H. G. (2025). Paclitaxel‐Coated Balloon for the Management of In‐Stent Coronary Restenosis: An Updated Meta‐Analysis and Trial Sequential Analysis. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31388

Vancouver

Oliveira VMR, Paiva AM, Alencar PLA, Oliveira IC, Alencar JVA, Zalaf FS, et al. Paclitaxel‐Coated Balloon for the Management of In‐Stent Coronary Restenosis: An Updated Meta‐Analysis and Trial Sequential Analysis. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31388

BibTeX
@article{Oliveira2025,
  author = {Oliveira, Vinícius M R and Paiva, Arthur Marot and Alencar, Pedro Lucas Alves and Oliveira, Izadora Caiado and Alencar, João Victor Alves and Zalaf, Felipe Schmaltz and Piai, Ricardo Figueiredo Paro and de Sousa, André Maroccolo and Moreira, Humberto Graner},
  title = {Paclitaxel‐Coated Balloon for the Management of In‐Stent Coronary Restenosis: An Updated Meta‐Analysis and Trial Sequential Analysis},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.31388}
}
Start for free →